These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 32526069)

  • 21. Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues.
    Wu H; Nie Y; Huse WD; Watkins JD
    J Mol Biol; 1999 Nov; 294(1):151-62. PubMed ID: 10556035
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A new approach for generating bispecific antibodies based on a common light chain format and the stable architecture of human immunoglobulin G
    De Nardis C; Hendriks LJA; Poirier E; Arvinte T; Gros P; Bakker ABH; de Kruif J
    J Biol Chem; 2017 Sep; 292(35):14706-14717. PubMed ID: 28655766
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Obtaining and characterization of monoclonal antibodies against recombinant extracellular domain of human epidermal growth factor receptor 2.
    Sarina N; Abeldenov S; Turgimbayeva A; Zhylkibayev A; Ramankulov Y; Khassenov B; Eskendirova S
    Hum Antibodies; 2018 Feb; 26(2):103-111. PubMed ID: 29036807
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tyrosine plays a dominant functional role in the paratope of a synthetic antibody derived from a four amino acid code.
    Fellouse FA; Barthelemy PA; Kelley RF; Sidhu SS
    J Mol Biol; 2006 Mar; 357(1):100-14. PubMed ID: 16413576
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design and expression of a stable bispecific scFv dimer with affinity for both glycophorin and N9 neuraminidase.
    Atwell JL; Pearce LA; Lah M; Gruen LC; Kortt AA; Hudson PJ
    Mol Immunol; 1996 Dec; 33(17-18):1301-12. PubMed ID: 9171890
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Designing Fcabs: well-expressed and stable high affinity antigen-binding Fc fragments.
    Wozniak-Knopp G; Stadlmayr G; Perthold JW; Stadlbauer K; Woisetschläger M; Sun H; Rüker F
    Protein Eng Des Sel; 2017 Sep; 30(9):657-671. PubMed ID: 28981753
    [TBL] [Abstract][Full Text] [Related]  

  • 27. "Two-in-One" approach for bioassay selection for dual specificity antibodies.
    Lee HY; Schaefer G; Lesaca I; Lee CV; Wong PY; Jiang G
    J Immunol Methods; 2017 Sep; 448():74-79. PubMed ID: 28579366
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monoclonal antibody therapeutics with up to five specificities: functional enhancement through fusion of target-specific peptides.
    LaFleur DW; Abramyan D; Kanakaraj P; Smith RG; Shah RR; Wang G; Yao XT; Kankanala S; Boyd E; Zaritskaya L; Nam V; Puffer BA; Buasen P; Kaithamana S; Burnette AF; Krishnamurthy R; Patel D; Roschke VV; Kiener PA; Hilbert DM; Barbas CF
    MAbs; 2013; 5(2):208-18. PubMed ID: 23575268
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Uncovering the Binding and Specificity of β-Wrapins for Amyloid-β and α-Synuclein.
    Orr AA; Wördehoff MM; Hoyer W; Tamamis P
    J Phys Chem B; 2016 Dec; 120(50):12781-12794. PubMed ID: 27934063
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A computational approach for studying antibody-antigen interactions without prior structural information: the anti-testosterone binding antibody as a case study.
    Koivuniemi A; Takkinen K; Nevanen T
    Proteins; 2017 Feb; 85(2):322-331. PubMed ID: 27936519
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression and purification of monospecific and bispecific recombinant antibody fragments derived from antibodies that block the CD80/CD86-CD28 costimulatory pathway.
    Dincq S; Bosman F; Buyse MA; Degrieck R; Celis L; de Boer M; Van Doorsselaere V; Sablon E
    Protein Expr Purif; 2001 Jun; 22(1):11-24. PubMed ID: 11388794
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DutaFabs are engineered therapeutic Fab fragments that can bind two targets simultaneously.
    Beckmann R; Jensen K; Fenn S; Speck J; Krause K; Meier A; Röth M; Fauser S; Kimbung R; Logan DT; Steegmaier M; Kettenberger H
    Nat Commun; 2021 Jan; 12(1):708. PubMed ID: 33514724
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Construction and humanization of a functional bispecific EGFR × CD16 diabody using a refolding system.
    Asano R; Nakayama M; Kawaguchi H; Kubota T; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
    FEBS J; 2012 Jan; 279(2):223-33. PubMed ID: 22074399
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Energetic and dynamic aspects of the affinity maturation process: characterizing improved variants from the bevacizumab antibody with molecular simulations.
    Corrada D; Colombo G
    J Chem Inf Model; 2013 Nov; 53(11):2937-50. PubMed ID: 24168661
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structural correlates of an anticarcinoma antibody: identification of specificity-determining residues (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only.
    Tamura M; Milenic DE; Iwahashi M; Padlan E; Schlom J; Kashmiri SV
    J Immunol; 2000 Feb; 164(3):1432-41. PubMed ID: 10640759
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mabfilin and Fabfilin - New antibody-scaffold fusion formats for multispecific targeting concepts.
    Kahl M; Settele F; Knick P; Haupts U; Bosse-Doenecke E
    Protein Expr Purif; 2018 Sep; 149():51-65. PubMed ID: 29704557
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen.
    Chen Y; Wiesmann C; Fuh G; Li B; Christinger HW; McKay P; de Vos AM; Lowman HB
    J Mol Biol; 1999 Nov; 293(4):865-81. PubMed ID: 10543973
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemical generation of bispecific antibodies.
    Doppalapudi VR; Huang J; Liu D; Jin P; Liu B; Li L; Desharnais J; Hagen C; Levin NJ; Shields MJ; Parish M; Murphy RE; Del Rosario J; Oates BD; Lai JY; Matin MJ; Ainekulu Z; Bhat A; Bradshaw CW; Woodnutt G; Lerner RA; Lappe RW
    Proc Natl Acad Sci U S A; 2010 Dec; 107(52):22611-6. PubMed ID: 21149738
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Toward Drug-Like Multispecific Antibodies by Design.
    Sawant MS; Streu CN; Wu L; Tessier PM
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33053650
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro affinity maturation to improve the efficacy of a hypoxia-inducible factor 1α single-domain intrabody.
    Hu M; Kang G; Cheng X; Wang J; Li R; Bai Z; Yang D; Huang H
    Biochem Biophys Res Commun; 2020 Sep; 529(4):936-942. PubMed ID: 32819602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.